Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ARO-INHBE
- Development stage
- Phase 2
- Lead developer
- Arrowhead Pharmaceuticals
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
ARO-INHBE is an investigational RNA interference (RNAi) therapeutic developed by Arrowhead Pharmaceuticals for the treatment of obesity and related metabolic diseases. It is designed to reduce hepatic expression of the Inhibin beta E chain (INHBE) gene and its secreted product, Activin E. Loss-of-function variants in INHBE are associated with improved fat distribution and a lower risk of metabolic diseases such as type 2 diabetes. By inhibiting this pathway, ARO-INHBE aims to increase lipolysis, reduce adipose hypertrophy and dysfunction, decrease visceral adiposity, improve insulin resistance, and potentially preserve lean muscle mass compared to currently approved obesity therapies. The drug is currently being evaluated in a Phase 1/2a clinical trial (AROINHBE-1001) involving adults with obesity[2][3][5][7].
- Other names
- INHBE RNAiARO-INHBEINHIBE GalNAc-siRNA
02
Targets
INHBE (Inhibin beta E chain)
Beyond the preview
Go deeper on ARO-INHBE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ARO-INHBE.